Trazimera

Trazimera is a biosimilar medicine that is used to treat certain types of breast cancer and gastric cancer. It is a biosimilar to the medicine Herceptin, which means it is highly similar in structure, safety, and efficacy to the original medicine, but is produced by a different company. Trazimera is produced by Pfizer, a multinational pharmaceutical company.

Composition[edit | edit source]

Trazimera contains the active substance trastuzumab, a monoclonal antibody that targets the HER2 receptor on cancer cells. By binding to these receptors, trastuzumab inhibits the growth and proliferation of cancer cells that overexpress the HER2 protein.

Indications[edit | edit source]

Trazimera is indicated for the treatment of patients with HER2 overexpressing breast cancer and gastric cancer. This includes patients with metastatic breast cancer, early breast cancer, and metastatic gastric cancer.

Administration[edit | edit source]

Trazimera is administered by intravenous infusion. The dosage and duration of treatment depend on the type and stage of the cancer, as well as the patient's overall health and response to treatment.

Side Effects[edit | edit source]

Like all medicines, Trazimera can cause side effects, although not everybody gets them. The most common side effects include fever, nausea, and diarrhea. Serious side effects can include heart problems, lung problems, and severe allergic reactions.

Regulatory Status[edit | edit source]

Trazimera was approved for use in the European Union in March 2019. In the United States, it was approved by the Food and Drug Administration (FDA) in March 2019.